Business ❯ Finance ❯ Market Trends ❯ Stock Market

Volatility

FDA Accepts Replimune’s Resubmitted RP1 Melanoma Filing, Sets April 2026 Decision

The review moves RP1 plus nivolumab into formal evaluation after a June rejection.

GameStop Tops Q2 Estimates, Reveals $528.6 Million in Bitcoin and a Special Warrant Dividend

Bullish Prices IPO at $37, Raises $1.11 B, Shares More Than Double in NYSE Debut